Printer Friendly

MERCK AND MEDIMMUNE TO JOINTLY DEVELOP AND MARKET PRODUCTS TO NEUTRALIZE HIV 1 STRAINS

 MERCK AND MEDIMMUNE TO JOINTLY DEVELOP AND MARKET
 PRODUCTS TO NEUTRALIZE HIV 1 STRAINS
 GAITHERSBURG, Md., Dec. 3 /PRNewswire/ -- MedImmune, Inc. (NASDAQ: MEDI) announced today that it and Merck & Co., Inc. (NYSE: MRK), had executed definitive agreements (agreement in principle announced Oct. 22, 1991) to jointly develop and market proprietary monoclonal antibodies for the prevention of infection by the Human Immunodeficiency Virus (HIV type 1).
 One proprietary monoclonal antibody to be researched by MedImmune and Merck has neutralized all the divergent laboratory strains of the HIV 1 tested in in-vitro studies. This monoclonal antibody will require additional years of animal and human clinical studies to determine its safety and efficacy.
 MedImmune, Inc. was founded in 1988 to develop, manufacture and market therapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The company's corporate headquarters are in Gaithersburg, Md.
 -0- 12/3/91
 /CONTACT: David Wright, executive vice president of MedImmune, 301-417-0770; Fred Spar of Kekst and Company, 212-593-2655, for MedImmune/
 (MEDI MRK) CO: MedImmune, Inc.; Merck & Co., Inc. ST: Maryland, New Jersey IN: MTC SU: JVN


JT -- NY085 -- 8893 12/03/91 16:26 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 3, 1991
Words:189
Previous Article:UNITED AIRLINES TRAFFIC INCREASES 5.3 PERCENT
Next Article:AMERICAN ADJUSTABLE RATE TERM TRUST INC. -- 1998 FILES A PUBLIC OFFERING
Topics:


Related Articles
IDEC PHARMACEUTICALS TO BEGIN HUMAN CLINICAL STUDY OF MONOCLONAL ANTIBODY-BASED THERAPEUTIC FOR TREATMENT OF HIV INFECTION
MEDIMMUNE'S CEO REVIEWS RECENT DEVELOPMENTS
MEDIMMUNE AND MERCK TO CONTINUE HIV PROGRAM
MEDIMMUNE PRODUCT SALES CONTINUE TO GROW IN THIRD QUARTER
MEDIMMUNE BEGINS CLINICAL TRIAL OF SECOND GENERATION PRODUCT FOR RSV DISEASE
Idenix Pharmaceuticals, Inc. Appoints Former Merck Executive to Direct Operations and Expand Commercialization Efforts.
MedImmune Strengthens Inflammatory Disease Pipeline Through Collaboration With Biowa.
MedImmune Strengthens Inflammatory Disease Pipeline Through Collaboration With BioWa.
Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters